Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Recruiting	Not applicable	2025-12-02		NCT07257510

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Peking University Third Hospital	243

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Peking University Third Hospital	Beijing	China	38

Clinical trials